trial · primary record
Esketamine 56 mg
Depressive Disorder, Treatment-Resistant
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 348 |
| Primary completion | 2029-09-12 |
| Primary endpoint | Double-Blind (DB) Treatment Phase: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Day 1 to the End of the 4-Week Double-Blind Treatment Phase |
| Registry ID | NCT07716098 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:56.030Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07716098
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.